ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 16 for:    Ad26.ZEBOV

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02376426
Recruitment Status : Completed
First Posted : March 3, 2015
Last Update Posted : December 8, 2016
Sponsor:
Information provided by (Responsible Party):
Crucell Holland BV

Brief Summary:
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered as heterologous prime-boost vaccine regimens in healthy adult participants.

Condition or disease Intervention/treatment Phase
Healthy Biological: MVA-BN-Filo Biological: Ad26.ZEBOV Biological: Placebo Phase 1

Detailed Description:
This is a randomized placebo-controlled, double-blind study evaluating the safety, tolerability and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV administered in different sequences and schedules to healthy adult participants. The study consists of a screening period of up to 28 days, a vaccination period in which participants will be vaccinated at Baseline [Day 1] followed by a boost on Day 29 or 57 and a post-boost follow-up, until all participants have had their 21-day post-boost visit (Day 50 or Day 78). The participants who received active vaccine will enter a long-term follow-up. The total duration of the study will be about 1 year for participants who received vaccine and about 3 months for participants who received placebo. Immunogenicity and safety will be monitored during the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults
Study Start Date : March 2015
Actual Primary Completion Date : September 2015
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ebola

Arm Intervention/treatment
Experimental: Group 1
Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
Biological: MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.

Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Experimental: Group 2
Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
Biological: MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.

Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Experimental: Group 3
Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
Biological: MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.

Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.

Experimental: Group 4
Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
Biological: MVA-BN-Filo
One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.

Biological: Ad26.ZEBOV
One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.

Biological: Placebo
One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.




Primary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: Up to 21 days post-boost (Day 50 for Groups 1 and 3 or Day 78 for Groups 2 and 4) ]
  2. Number of Participants With Serious Adverse Events [ Time Frame: Up to the end of long-term follow-up (day 360) ]
  3. Number of participants with reactogenicity (ie, solicited local and systemic adverse events) [ Time Frame: 1 week after each study vaccine administration ]

Secondary Outcome Measures :
  1. Immune responses to the study vaccine regimens as measured by a virus neutralization assay [ Time Frame: Groups 1 and 3: Days 1 (pre-vaccination), 8, 29 (pre-vaccination), 36, 50, 113, 180, 240, and 360; Groups 2 and 4: Days 1 (pre-vaccination), 8, 29, 57 (pre-vaccination), 64, 78, 141, 180, 240, and 360) ]
  2. Immune responses to the study vaccine regimens measured by an enzyme-linked immunosorbent assay (ELISA) [ Time Frame: Groups 1 and 3: Days 1 (pre-vaccination), 8, 29 (pre-vaccination), 36, 50, 113, 180, 240, and 360; Groups 2 and 4: Days 1 (pre-vaccination), 8, 29, 57 (pre-vaccination), 64, 78, 141, 180, 240, and 360) ]
  3. Immune responses to the study vaccine regimens as measured by an Enzyme-linked Immunospot Assay (ELISpot) [ Time Frame: Groups 1 and 3: Days 1 (pre-vaccination), 8, 29 (pre-vaccination), 36, 50, 113, 180, 240, and 360; Groups 2 and 4: Days 1 (pre-vaccination), 8, 29, 57 (pre-vaccination), 64, 78, 141, 180, 240, and 360) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must be healthy on the basis of physical examination, medical history, and the investigator's clinical judgment
  • Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test at screening, a negative urine pregnancy test immediately prior to each study vaccine administration, and practice adequate birth control measures from 28 days before the prime vaccination until at least 3 months after the boost vaccination as specified in the study protocol. If not heterosexually active at screening, must agree to practice adequate birth control measures if they become heterosexually active during their participation in the study (from screening onwards until at least 3 months after the boost vaccination).
  • Must be available and willing to participate for the duration of the study visits and follow-up, provide verifiable identification, and have a means to be contacted

Exclusion Criteria:

  • Has been vaccinated with a candidate Ebola vaccine
  • Has been diagnosed with Ebola disease or exposed to Ebola including travel to West Africa in the last 12 months. West Africa includes but is not limited to the countries of Guinea, Liberia, Mali, and Sierra Leone. Participants who anticipate traveling to epidemic Ebola areas before the start of the long-term follow-up period will also be excluded. During the long-term follow-up period, travel to epidemic Ebola areas is allowed but during this period sampling can only take place if participant has returned at least 1 month from the epidemic Ebola area to ensure the samples are not carrying the Ebola-virus
  • Has received any Ad26- or MVA-based candidate vaccine in the past
  • Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines), including known allergy to egg or aminoglycosides
  • A woman who is pregnant or breast-feeding, or planning to become pregnant while enrolled in the study or within 3 months after the boost vaccination
  • History of diabetes mellitus type 1 or type 2, including cases controlled with diet alone; thyroidectomy, or thyroid disease requiring medication during the last 12 months; uncontrolled hypertension as defined in the study protocol; or, major psychiatric illness and/or substance abuse problems during the past 12 months that in the opinion of the investigator would preclude participation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02376426


Locations
Kenya
Nairobi, Kenya
Sponsors and Collaborators
Crucell Holland BV
Investigators
Study Director: Crucell Holland BV Clinical Trial Crucell Holland BV

Responsible Party: Crucell Holland BV
ClinicalTrials.gov Identifier: NCT02376426     History of Changes
Other Study ID Numbers: CR106458
VAC52150EBL1003 ( Other Identifier: Crucell Holland BV )
First Posted: March 3, 2015    Key Record Dates
Last Update Posted: December 8, 2016
Last Verified: December 2016

Keywords provided by Crucell Holland BV:
Healthy
Ebola viruses
Ebola Viral Disease (EVD)
Filoviruses
Monovalent vaccine
Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga variant glycoprotein (Ad26.ZEBOV)
Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector
Safety
Immunogenicity